Evercore analyst Vijay Kumar maintains $Medtronic (MDT.US)$ with a buy rating, and adjusts the target price from $100 to $104.
According to TipRanks data, the analyst has a success rate of 57.6% and a total average return of 5.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Medtronic (MDT.US)$'s main analysts recently are as follows:
The recent surge in medical technology stocks is under scrutiny as the sector approaches third-quarter financial disclosures. There is a cautious stance going into the earnings season, as this period is traditionally the most challenging for MedTech, presenting a critical examination of the 2025 outlook. Additionally, commentary regarding projections for the next year may significantly influence stock performance shortly.
In MedTech, the positive trend in utilization is expected to continue into Q3, and the outlook for capital expenditures into the following year appears to remain robust. For life science tools, bioprocess trends are anticipated to improve in the latter half of the year. However, discussions are ongoing regarding the outlook for instruments and the impact of China's stimulus, in light of the recent uptick in the sector's stock performance. Medtronic, among other companies in the group, has been included on a list for tactical outperformance, with expectations set for the upcoming Q3 results, while Exact Sciences remains on this list as well.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Evercore分析師Vijay Kumar維持$美敦力 (MDT.US)$買入評級，並將目標價從100美元上調至104美元。
根據TipRanks數據顯示，該分析師近一年總勝率為57.6%，總平均回報率為5.6%。
此外，綜合報道，$美敦力 (MDT.US)$近期主要分析師觀點如下：
醫療科技股票最近的激增受到了審查，隨着該板塊接近第三季度財務披露，人們對進入收益季持謹慎態度，因爲這一時期傳統上是醫療科技行業最具挑戰性的時期，對2025年的前景提出了關鍵審查。此外，關於明年預測的評論可能會極大影響股票表現。
在醫療科技領域，利用率的積極趨勢預計將持續到第三季度，並且對明年的資本支出前景似乎仍然強勁。對於生命科學工具，生物工藝趨勢有望在年底後半段改善。然而，關於儀器前景和中國刺激措施的影響的討論仍在繼續，考慮到該板塊股票表現近期的回升。美敦力等其他公司已被列入戰術優勢名單，預計將在即將發佈的第三季度成績中表現出色，精密科學也繼續留在這一名單上。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
